RxDoctor Payments Data

Ana Beauchamp-Irizarry, MD

Internal Medicine · Ponce, PRNPI 1104018175

Payments from drug & device makers

$4,438in general payments, 2019–2025

Across 184 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$563
  • Sanofi-aventis U.S. LLC$399
  • E.r. Squibb & Sons, L.L.C.$351
  • Johnson & Johnson$246
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$184
  • plus $586 from 7 others

What the payments were for

  • Food & beverage$4,37899%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,438 in reported general payments places this provider in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,930
Medicare patients
16
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol263$245,199
JardianceEmpagliflozin151$166,528
GlyxambiEmpagliflozin/Linagliptin125$107,138
Synjardy XrEmpagliflozin/Metformin Hcl105$104,975
XareltoRivaroxaban100$93,552
Trijardy XrEmpaglifloz/Linaglip/Metformin97$89,057
EliquisApixaban101$89,043
OzempicSemaglutide75$75,171
SynthroidLevothyroxine Sodium547$59,318
TrulicityDulaglutide38$49,728
Xigduo XrDapaglifloz Propaned/Metformin48$44,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$43,192
BrilintaTicagrelor37$33,491
Repatha SyringeEvolocumab41$27,101
JanumetSitagliptin Phos/Metformin Hcl29$24,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Trijardy Xr, Synjardy$563$556,001584 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$2,109$287,757314 claims
Johnson & JohnsonXarelto$246$93,552100 claims
GSKTrelegy Ellipta, Breo Ellipta$145$62,652110 claims
AbbVieSynthroid$42$59,318547 claims
MerckJanumet, Januvia$169$46,36845 claims
Sanofi-aventis U.S. LLCLantus$399$16,561153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →